Company Name: |
MedChemexpress LLC
|
Tel: |
021-58955995 |
Email: |
sales@medchemexpress.cn |
Products Intro: |
Product Name:KB3022 CAS:101001-34-7 Purity:500RMB/1mg Package:>98%
|
|
| KB 3022 Basic information |
Product Name: | KB 3022 | Synonyms: | KB 3022;2-[4,5-Bis(4-methoxyphenyl)thiazol-2-yl]-1H-pyrrole-1-acetic acid ethyl ester;KBT-3022;1H-Pyrrole-1-acetic acid, 2-[4,5-bis(4-methoxyphenyl)-2-thiazolyl]-, ethyl ester;KB3022 (KBT3022;ethyl 2-[4,5-bis(4-methoxyphenyl)thiazol-2-yl]-pyrrole-1-acetate;ethyl 2-(2-(4,5-bis(4-methoxyphenyl)thiazol-2-yl)-1H-pyrrol-1-yl)acetate;Cyclooxygenase,KBT-3022,Pamicogrel,Inhibitor,inhibit,KBT 3022,COX | CAS: | 101001-34-7 | MF: | C25H24N2O4S | MW: | 448.53 | EINECS: | | Product Categories: | | Mol File: | 101001-34-7.mol | |
| KB 3022 Chemical Properties |
Melting point | 132.5-135.5° | Boiling point | 600.3±65.0 °C(Predicted) | density | 1.22±0.1 g/cm3(Predicted) | storage temp. | 2-8°C | solubility | DMF:10.0(Max Conc. mg/mL);22.0(Max Conc. mM) DMF:PBS (pH 7.2) (1:1):0.5(Max Conc. mg/mL);1.1(Max Conc. mM) DMSO:5.0(Max Conc. mg/mL);11.0(Max Conc. mM) | form | A crystalline solid | pka | 2.68±0.10(Predicted) | color | Off-white to pink |
Toxicity | LD50 orally in male mice: >3000 mg/kg (Yoshino) |
| KB 3022 Usage And Synthesis |
Biological Activity | Pamicogrel (KBT3022) is an inhibitor of cyclooxygenase (COX) with platelet anti-aggregation properties. | in vitro | KB 3022 is a cyclooxygenase inhibitor with platelet anti-aggregatory properties which is under development by Kanebo for chronic arterial occlusion. It also has potential in both prophylaxis and treatment of ischemic brain injury. | target | Target | Value | COX () | table>
| KB 3022 Preparation Products And Raw materials |
|
Tag:KB 3022(101001-34-7)
Related Product Information
|
2-pyrrol-1-ylacetic acid
KB 3022
4,5-DIPHENYL-2-METHYLTHIAZOLE
4-(4-METHOXY-PHENYL)-2-METHYL-THIAZOLE
|
According to the laws, regulations and policies related to "patent products", the sale of this product is prohibited!
ChemicalBook prompt
The patent owner or licensee of the product has not released any relevant information for the time being.
|